The Drug Control Department has issued a public interest announcement in which it states that it prohibits the sale and consumption of syrup Coldrif because of falsification that damages health.
In the announcement of October 10, the ministry said that it noted that government analysis at the beginning of the month found that syrup cold was declared “not standard quality”. He added that the drug has been reported to be falsified because it contains diethylene glycol, causing wording to damage health.
“As a precautionary measure, all parties are focused on delaying the aforementioned cough syrup with immediate effect and do not interest in the purchase, sale and distribution of this syrup cough.
Also read | Watch: Rohit Sharma shouts at Security to stop a small child – viral video
Syrup “killer” claims the lives of 20 children
Delhi is not alone, Kerala, Madhya Pradesh, Tamil Nadu and Pandjab also forbade sale, distribution and use of Coldriff after death 20 children in Madhya Pradesh for alleged drug contamination. Four children, representatives of the main minister of health Madhya Pradesh Rajendra Shukl, are treated.
Meanwhile, the CEO of drugs in India (DCGI) issued a directive for all countries and territories (UTS), which called for strict adherence to drug rules, 1945, for testing raw materials and finished pharmaceutical formulations, and reported.
In the letter of 7 October, Dr. Rajeev Singh Raghuvanki DCGI “Critical importance of testing of new materials, including auxiliary substances, before using them in the production of pharmaceutical formulations”.
Also read | Trade conversations in USA-Chinese fail? Why Trump announced 100% of tariffs, export curbs
What did Delhi’s drug department say? Full text
“He realized this office that the Coldrif syrup was declared” not the standard quality “of a government analyst, a laboratory for drug testing, food and drug management, Madhya Pradesh. Drive details are as follows:
Name of drug: COLDRIF SYRUP (paracetamol, phenylefrin hydrochloride, syrup maleate chlorpheniramine),
SAIR NUMBER: SR-13 production
Date: May 2025, expiration date: April 2027,
Manufacturer: Seesan Pharmaceutical, manufacturer. No. 787, Bangalore Highways, Sunguvachatram (Mathra), Kancheepuram Ditrict, 612106 from Tamil Nadu.
It is reported that the above formulation of the drug is falsified because it contains diethylene glycol (42.28% hm./obj.), Which causes the formulation of the drug to damage health.
With regard to this, as preventive measures, all parties involved hereby focus on the solution of the above -mentioned syrup cough with immediate effect and do not deal with the purchase, sale and distribution of this syrup cough. The general public is also sensitized to refrain from using this syrup cough.
Assistance of all stakeholders to strictly implement and widely spread this public announcement in a highly requested. Issued in the public interest. ”
(Tagstotranslate) Coldrif syrup
